NCT00662038View on ClinicalTrials.gov

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,058

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

pirfenidone

Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.

Trial Locations (1)

94080-4990

Genentech, Inc., South San Francisco

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Genentech, Inc.

INDUSTRY

NCT00662038 - Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter